Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

EQ

Equillium (EQ)

Equillium Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EQ
DateTimeSourceHeadlineSymbolCompany
14/12/202408:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
13/12/202409:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQEquillium Inc
13/12/202409:43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EQEquillium Inc
13/12/202408:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
15/11/202413:50Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:EQEquillium Inc
14/11/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
14/11/202408:01Business WireEquillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical UpdatesNASDAQ:EQEquillium Inc
14/11/202400:00Business WireEquillium to Present at the Stifel Healthcare ConferenceNASDAQ:EQEquillium Inc
13/11/202400:00Business WireEquillium Announces Poster Presentation at the Society for Immunotherapy of CancerNASDAQ:EQEquillium Inc
01/11/202403:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EQEquillium Inc
31/10/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
31/10/202422:00Business WireEquillium Maintains Rights to Itolizumab Following Ono PartnershipNASDAQ:EQEquillium Inc
31/10/202411:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQEquillium Inc
30/10/202407:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQEquillium Inc
07/10/202423:00Business WireEquillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of CancerNASDAQ:EQEquillium Inc
18/09/202408:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQEquillium Inc
10/09/202422:00Business WireEquillium to Present at the Stifel Virtual Inflammation & Immunology SummitNASDAQ:EQEquillium Inc
04/09/202422:00Business WireEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:EQEquillium Inc
28/08/202422:00Business WireEquillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor ConferenceNASDAQ:EQEquillium Inc
09/08/202406:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EQEquillium Inc
09/08/202406:01Business WireEquillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical HighlightsNASDAQ:EQEquillium Inc
06/08/202422:00Business WireEquillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host DiseaseNASDAQ:EQEquillium Inc
24/07/202406:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
19/07/202404:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
19/07/202403:57Business WireEquillium Announces Second Quarter 2024 Estimated Cash and Investments BalanceNASDAQ:EQEquillium Inc
02/07/202422:00Business WireEquillium to Participate in Upcoming Investor ConferencesNASDAQ:EQEquillium Inc
12/06/202422:00Business WireEquillium to be included in the Russell Microcap® IndexNASDAQ:EQEquillium Inc
05/06/202422:00Business WireEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:EQEquillium Inc
04/06/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
04/06/202422:00Business WireEquillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia AreataNASDAQ:EQEquillium Inc
 Showing the most relevant articles for your search:NASDAQ:EQ